Helsinn Healthcare S.A., Petitioner v. Teva Pharmaceuticals USA, Inc., et al.

  1. August 31, 2018

    DOJ, MassBio Back Helsinn In High Court On-Sale Bar Fight

    The U.S. Department of Justice, the Massachusetts Biotechnology Council and nine other amici urged the justices to overturn a Federal Circuit decision expanding the America Invents Act's on-sale bar, saying it conflates confidential development agreements for public disclosures and will harm all but the largest drug companies.

  2. August 28, 2018

    On-Sale Bar Doesn't Cover Secret Prior Art, Justices Told

    The America Invents Act amended the so-called on-sale bar to align U.S. patent law with other countries and eliminate secret prior art from being used to invalidate patents, one of the law's main sponsors has told the U.S. Supreme Court in a case involving a Helsinn nausea drug patent.

  3. August 23, 2018

    On-Sale Bar Ruling 'Profoundly Erroneous,' High Court Told

    Helsinn Healthcare SA fired its opening salvo Thursday in a case that will require the U.S. Supreme Court to interpret changes made in the America Invents Act to the on-sale bar rule in patent cases, calling a ruling that invalidated the company's nausea drug patent "profoundly erroneous."

  4. July 06, 2018

    Patent Cases To Watch In The 2nd Half Of 2018

    From the impact of the America Invents Act on the scope of the on-sale bar to sovereign immunity at the Patent Trial and Appeal Board, courts have a number of important issues to consider as we move into the second half of 2018. Here’s a look at some of the issues — and cases that implicate them — that will be worth watching over the next six months.

  5. June 25, 2018

    High Court To Hear Patent Case Over On-Sale Bar

    The U.S. Supreme Court on Monday agreed to review a Federal Circuit decision that invalidated a Helsinn Healthcare SA nausea drug patent and to interpret changes made in the America Invents Act to the on-sale bar rule.

  6. May 23, 2018

    Teva Urges Justices To Reject Fed. Circ. On-Sale Bar Appeal

    Teva Pharmaceuticals has urged the U.S. Supreme Court not to review the Federal Circuit's holding on the America Invents Act's changes to the on-sale bar rule, arguing Helsinn Healthcare is wrong to claim that the ruling puts "countless" patents at risk.

  7. April 03, 2018

    Lawmaker, IP Orgs Contest On-Sale Bar Ruling At High Court

    Intellectual property groups and the lawmaker behind the America Invents Act urged the U.S. Supreme Court on Monday to take up Helsinn Healthcare TA's petition and reverse a Federal Circuit decision holding that sales in which an invention isn't publicly disclosed invalidate patents under the AIA's on-sale bar rule.